Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermol 500 is an antimicrobial emollient lotion developed by Dermal Laboratories for the management of dry and pruritic skin conditions, including eczema and dermatitis. It is formulated with four active ingredients: benzalkonium chloride and chlorhexidine dihydrochloride, which provide broad-spectrum antimicrobial activity by disrupting bacterial cell membranes, and liquid paraffin and isopropyl myristate, which act as emollients to moisturize the skin and reinforce the epidermal barrier. The product is designed to reduce skin colonization by pathogens like *Staphylococcus aureus* while preventing moisture loss. In addition to its use as a leave-on emollient, it can be used as a soap substitute. It has also been investigated in Phase 4 clinical trials for the prevention of pin site infections following circular frame orthopedic surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermol 500.